What is Edgewise Therapeutics, Inc.'s depreciation?

Edgewise Therapeutics, Inc. (EWTX) reported depreciation of $537K in Q1 2026.

How has Edgewise Therapeutics, Inc.'s depreciation changed year-over-year?

Edgewise Therapeutics, Inc.'s depreciation increased by 4.7% year-over-year, from $513K to $537K.

What is the long-term trend for Edgewise Therapeutics, Inc.'s depreciation?

Over 4 years (2021 to 2025), Edgewise Therapeutics, Inc.'s depreciation has grown at a 60.4% compound annual growth rate (CAGR), from $308K to $2.04M.

Edgewise Therapeutics, Inc. EWTX Depreciation

Depreciation at other companies

Catalyst PharmaceuticalCPRX

——

AbbottABT

——

InsmedINSM

——

Other financials

Income statement

See full

Operating income-$54.1M-17.7%

Net income-$49.0M-20.1%

EPS (diluted)-$0.46-7.0%

Balance sheet

See full

Cash & equivalents$33.2M-33.5%

Total debt$3.8M-16.8%

Total equity$493.2M+14.8%

Total assets$518.5M+14.1%

Cash flow

See full

Operating cash flow-$42.5M-12.4%

CapEx$260.0K+491%

Free cash flow-$42.8M-12.9%

Valuation

See full

Market cap$4.18B+61.3%

Returns & leverage

See full

Return on equity-38.1%+13.4pp

Debt / equity0×0.0×

Current ratio22.6×+1.6×

Where this comes from

Reported directly by Edgewise Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:Depreciation.

The official record: Edgewise Therapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Edgewise Therapeutics, Inc.'s depreciation.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Edgewise Therapeutics, Inc.'s depreciation?: Edgewise Therapeutics, Inc. (EWTX) reported depreciation of $537K in Q1 2026.
How has Edgewise Therapeutics, Inc.'s depreciation changed year-over-year?: Edgewise Therapeutics, Inc.'s depreciation increased by 4.7% year-over-year, from $513K to $537K.
What is the long-term trend for Edgewise Therapeutics, Inc.'s depreciation?: Over 4 years (2021 to 2025), Edgewise Therapeutics, Inc.'s depreciation has grown at a 60.4% compound annual growth rate (CAGR), from $308K to $2.04M.